<a href="https://laohu8.com/S/THAR">Tharimmune Inc.</a> Announces $2.5 Million Private Placement to Fund Clinical Development and Working Capital
Tharimmune Inc. has announced a private placement agreement with accredited individual and institutional investors to raise approximately $2.5 million. The company will issue 1,551,351 shares of common stock, pre-funded warrants for 137,838 shares, Series A warrants for 1,689,189 shares at $1.29 per share, and Series B warrants for 844,572 shares at $3.00 per share. The transaction, expected to close on June 20, 2025, pending customary conditions, will see President Street Global acting as the exclusive placement agent. The funds will support Tharimmune's clinical development and working capital needs.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tharimmune Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001641172-25-015675), on June 20, 2025, and is solely responsible for the information contained therein.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。